Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults  by Hopkins, Robert J. et al.
R
s
d
i
R
Y
a
b
c
d
a
A
R
R
A
A
P
N
K
B
V
A
C
P
1
[
c
i
h
0Vaccine 34 (2016) 2096–2105
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
andomized,  double-blind,  active-controlled  study  evaluating  the
afety  and  immunogenicity  of  three  vaccination  schedules  and  two
ose  levels  of  AV7909  vaccine  for  anthrax  post-exposure  prophylaxis
n  healthy  adults
obert  J.  Hopkinsa,∗, Gurdyal  Kalsi a,1, Victor  M.  Montalvo-Lugoa, Mona  Sharmaa,
ukun  Wua,  Derek  D.  Museb, Eric  A.  Sheldonc, Frank  C.  Hampeld, Laurence  Lemialea
Emergent BioSolutions Inc., 400 Professional Drive, Gaithersburg, MD 20879, USA
Jean Brown Research, 1045 East 3900 South, Suite 100, Salt Lake City, UT 84124, USA
Miami Research Associates, 6141 Sunset Drive, Suite 301, South, Miami, FL 33143, USA
Central Texas Health Research, 705-A Landa, New Braunfels, TX 78130, USA
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 3 December 2015
eceived in revised form 15 February 2016
ccepted 3 March 2016
vailable online 12 March 2016
ACS:
CT01770743
eywords:
ioThrax® (Anthrax Vaccine Adsorbed)
accine
nthrax
PG 7909
ost-exposure prophylaxis
a  b  s  t  r  a  c  t
AV7909  vaccine  being  developed  for post-exposure  prophylaxis  of anthrax  disease  may  require fewer
vaccinations  and  reduced  amount  of antigen  to  achieve  an  accelerated  immune  response  over  BioThrax®
(Anthrax  Vaccine  Adsorbed).
A  phase  2,  randomized,  double-blind,  BioThrax  vacccine-controlled  study  was  conducted  to  evaluate
the  safety  and  immunogenicity  of three  intramuscular  vaccination  schedules  and two  dose  levels  of
AV7909  in 168  healthy  adults.  Subjects  were  randomized  at a 4:3:2:4:2  ratio  to 5  groups:  (1) AV7909  on
Days  0/14;  (2) AV7909  on  Days  0/28;  (3) AV7909  on  Days  0/14/28;  (4)  half  dose  AV7909  on  Days  0/14/28;
and  (5)  BioThrax  vaccine  on  Days  0/14/28.
Vaccinations in  all groups  were  well  tolerated.  The  incidences  of  adverse  events  (AEs)  were  79% for
AV7909  subjects  and  65%  for  BioThrax  subjects;  92% of  AV7909  subjects  and  87%  of  BioThrax  subjects
having  AEs  reported  Grade  1–2  AEs.  No  serious  AEs  were  assessed  as potentially  vaccine-related,  and  no
AEs  of  potential  autoimmune  etiology  were  reported.  There  was no discernible  pattern  indicative  of  a
safety concern  across  groups  in  the incidence  or severity  of reactogenicity  events.
Groups  2–4 achieved  success  for the  primary  endpoint,  demonstrated  by  a  lower  95% conﬁdence  limit
of  the percentage  of subjects  with  protective  toxin  neutralizing  antibody  NF50 values (≥0.56)  to  be  ≥40%
at  Day 63.  Group  1 marginally  missed  the  criterion  (lower  bound  95%  conﬁdence  limit of 39.5%).  Immune
responses  were  above  this threshold  for Groups  1, 3  and  4 at Day  28  and  all  groups  at Day  42.
Further  study  of  an  AV7909  two-dose  schedule  given  2  weeks  apart  is warranted  in  light  of  the  favorable
tolerability  proﬁle  and  immunogenicity  response  relative  to  three  doses  of  BioThrax  vaccine,  as  well  as
preliminary  data  from  nonclinical  studies  indicating  similar  immune  responses  correlate  with  higher
survival  for  AV7909  than  BioThrax  vaccine.
ublis© 2016  The  Authors.  P
. Introduction
The combination of BioThrax® (Anthrax Vaccine Adsorbed
AVA]) and CPG 7909 (a synthetic immunostimulatory oligonu-
leotide), known as AV7909, is being clinically investigated for
ts potential to achieve an accelerated immune response for
∗ Corresponding author. Tel.: +1 240 631 6441.
E-mail address: hopkinsr@ebsi.com (R.J. Hopkins).
1 Present afﬁliation: Independent consultant.
ttp://dx.doi.org/10.1016/j.vaccine.2016.03.006
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
protection against anthrax disease in a post-exposure prophylaxis
(PEP) setting. A 3-dose series of BioThrax vaccine administered
subcutaneously (SC) at 0, 2, and 4 weeks alongside a 60-day
antimicrobial regimen is approved by the United States (US) Food
and Drug Administration (FDA) and recommended by the Advisory
Committee on Immunization Practices for PEP of anthrax [1].
Compliance with the antimicrobial regimen has been problematic:
less than 50% of exposed individuals were compliant following the
2001 anthrax attacks in the US [2]. An enhanced anthrax vaccine
including CPG 7909 may require fewer vaccine doses and reduced
amount of antigen, potentially promoting compliance with the full
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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accine schedule while providing a greater probability of survival.
arlier protection may  reduce the duration of antimicrobials
equired.
Two phase 1 trials exploring the AV7909 vaccine have been com-
leted in 174 healthy adults. In the initial trial, an admixture prior to
njection of 0.5 mL  BioThrax vaccine + 1 mg  CPG 7909 signiﬁcantly
ncreased serum levels of anti-protective antigen (PA) antibody and
oxin neutralizing antibody (TNA) compared with BioThrax vaccine
lone, including at a much earlier time point, by at least 3 weeks [3].
accination was well tolerated with a trend toward increased fre-
uency and severity of local and systemic reactions in the BioThrax
accine + CPG 7909 group. The second trial identiﬁed a formula-
ion of AV7909 for further clinical development (0.5 mL  BioThrax
accine + 0.25 mg  CPG 7909) that produced an enhanced immune
esponse without increased reactogenicity [4]. This formulation
as evaluated in the phase 2 trial described here.
The primary objectives of the current phase 2 trial were to assess
afety of the selected AV7909 formulation and assess immuno-
enicity measured as TNA 50% neutralization factor (NF50) at Day
3. As a secondary objective, immunogenicity at earlier time points
as also assessed (Days 28, 42).
. Materials and methods
.1. Investigational products
All vaccines were administered intramuscularly (IM) in the
eltoid muscle using a 25-ga sterile needle and 1 cm3 syringe. Alter-
ating arms were used for each successive injection. Refrigeration
ithin the range of 2–8 ◦C was required for the AV7909 and AVA
accines.
AVA, manufactured by Emergent BioSolutions Inc. (Lansing,
ichigan, US) and previously described [4], is a sterile, milky-white
uspension made from cell-free ﬁltrates of microaerophilic cultures
f an avirulent, nonencapsulated strain of Bacillus anthracis. Com-
ercial lot FAV392A was supplied for the study. A single vaccine
ose was 0.5 mL.
AV7909 drug product, a pre-formulated, sterile, milky-white
uspension manufactured by Par Pharmaceutical (Rochester,
ichigan, US), is composed of AVA bulk drug substance and CPG
909 adjuvant. Approximately 6.2 mL  of AV7909 vaccine was  sup-
lied in glass vials as a multidose ﬁnal drug product. Each full dose
ontained 0.5 mL  AVA + 0.25 mg  CPG 7909 and each half-dose con-
ained 0.25 mL  AVA + 0.125 mg  CPG 7909. Lot TC2994 was used in
he study.
Placebo of 0.5 mL  of sterile, colorless, preservative-free saline
or injection (0.9% sodium chloride) was administered in Groups 1
nd 2 to mask the dosing schedule.
.2. Study design
This was a phase 2, multicenter, randomized, parallel-group,
ctive-controlled, double-blind study evaluating the safety and
mmunogenicity of AV7909 for PEP of anthrax disease in 168 sub-
ects recruited at four clinical research centers in the US. Eligible
ubjects were aged 18–50 years and in general good health, hav-
ng no previous history of exposure to anthrax or anthrax vaccine
nd no chronic conditions or exposure to products that may  have
iased an evaluation of the immune response.
Subjects were allocated to treatment groups according to a
omputer-generated randomization list prepared by an inde-
endent, unblinded statistician. An unblinded site staff member
ccessed the interactive web response system to receive a printout
ith the treatment assignment, which was subsequently secured
n a limited-access area to prevent accidental unblinding. Subjects4 (2016) 2096–2105 2097
were randomized using a 4:3:2:4:2 ratio in blocks of 15 to 1 of 5
groups comprising 3 IM vaccination schedules and 2 dose levels:
(1) full dose AV7909 on Days 0/14; (2) full dose AV7909 on Days
0/28; (3) full dose AV7909 on Days 0/14/28; (4) half dose AV7909 on
Days 0/14/28; and (5) full dose BioThrax vaccine on Days 0/14/28.
Randomization was stratiﬁed to ensure at least 40% of subjects per
group were of each gender and that equal proportions of subjects
were between 18–30 or 31–50 years of age.
Procedures were instituted to ensure investigators, all staff per-
forming subject assessments, and all subjects remained blinded
to treatment assignment. Vaccine preparation and administration
were performed by unblinded site personnel. All syringes were cov-
ered during vaccine administration, leaving only the hub exposed.
The BioThrax immunization regimen used in this study has been
shown to achieve circulating TNA titers that have conferred at least
70% survival to rabbits and non-human primates after B. anthracis
spore challenge [5,6].
The trial was  conducted in accordance with Good Clinical
Practice and ethical principles that have their origin in the Decla-
ration of Helsinki. Informed consent was  obtained from subjects
at Screening after informing them about the study and associ-
ated risks. Safety oversight was supplemented by an independent
safety monitoring committee (SMC) consisting of 3 physicians, and
also independent safety monitors (ISMs). Interim safety data were
reviewed by the SMC  after 50 subjects and 100 subjects had com-
pleted the Day 14 visit. No safety concerns were identiﬁed during
these reviews.
2.3. Immunogenicity assessment
Serum samples for determination of immunogenicity were col-
lected on Days 0 (before vaccination), 21, 28 (before vaccination),
35, 42, 49, 63, and 84. Samples were tested using a validated,
high-throughput, cell-based bioassay by Battelle Memorial Insti-
tute (West Jefferson, Ohio, US) to measure neutralization of anthrax
lethal toxin (LT) by antibodies generated in response to vaccination.
An NF50 value was  calculated as the ratio of effective dose that pro-
vided 50% neutralization (ED50) of the human test sample to ED50 of
a human reference serum from subjects vaccinated with BioThrax
vaccine. The reference standard, AVR801, was the same used in the
prior clinical studies of AV7909 [3,4].
The primary immunogenicity outcome was the lower bound of
the 95% conference interval (CI) for the proportion of subjects in
each group with Day 63 NF50 values ≥0.56, the threshold of 70% pro-
tection established for BioThrax vaccine. Secondary outcomes also
focused on an evaluation of immunogenicity based on proportion
of subjects meeting or exceeding the NF50 threshold of protection
at earlier time points (at Day 28 in Groups 1, 3, and 4; at Day 42 in
all groups).
2.4. Safety assessment
Subjects were evaluated for safety at clinic visits from Day 0
to Day 84 and also by phone contacts occurring 6 months and 12
months after the last vaccination.
Safety was  assessed through Day 84 by clinical laboratory test
results graded against a modiﬁed version of the FDA’s toxicity grad-
ing scale [7], monitoring of adverse events (AEs; including serious
AEs [SAEs]; and AEs of special interest [AESI], deﬁned as having a
potential autoimmune etiology), vital signs, and physical examina-
tions. Serum samples were collected on Days 0 (before vaccination),
42, and 84 for autoantibody testing (anti-nuclear antibodies and
rheumatoid factor) if any subjects reported AESIs during the study.
Notably, AEs were recorded for Grade 3 or higher laboratory test
abnormalities, any clinical laboratory or vitals sign abnormalities
considered clinically signiﬁcant by the investigator, and any new or
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hanged-in-severity abnormal physical examination ﬁnding after
he ﬁrst vaccination.
Reactogenicity (i.e., solicited injection site and systemic reac-
ions) was assessed and reported by subjects using e-diaries for 7
ays after each vaccination, or longer if reactions persisted beyond
 days; and assessed and reported by the investigator at clinic visits
 and 14 days after each vaccination. Events classiﬁed as Grade 3 in
he e-diary prompted a follow-up telephone call from the physician
nd decision for an unscheduled visit for assessment of the injec-
ion site, if needed. Reactogenicity reactions were not also recorded
s AEs.
Any subject who discontinued vaccinations was encouraged to
ontinue safety follow up by attending subsequent visits through
ay 84, and also asked to participate in the 6- and 12-month safety
ollow-up telephone calls.
.5. Statistical methods and study populations
Descriptive analyses were performed to demonstrate demo-
raphic distribution, as well as vaccine immunogenicity and safety.
ontinuous variables were summarized using number of non-
issing observations (n), arithmetic or geometric mean where
ppropriate, median, standard deviation, minimum, maximum,
nd 95% conﬁdence interval (CI). Categorical variables were sum-
arized using the frequency count and the percentage of subjects
n each category as well as its exact Binomial 95% conﬁdence inter-
al. No imputation was made for missing values. No conﬁdence
evel was adjusted for multiple 95% CIs. All statistical tabulations
nd analyses were performed using SAS®, version 9.1.3.
Demographic analyses were conducted for the intent-to-treat
ITT) population, deﬁned as all subjects who were randomized to
ne of the ﬁve groups.
Immunogenicity analyses were conducted on the per protocol
PP) population, deﬁned as subjects who were randomized and did
ot have any of the following deviations: (a) missing or out of win-
ow vaccination visit at Day 14 or 28; (b) incorrect dose of vaccine at
ne or more visits; (c) vaccine dose associated with a temperature
xcursion prior to administration at any visit; (d) use of prohibited
r restricted medications prior to Day 63 which may  have impacted
mmune response to vaccination; and (e) missing immunogenicity
ata at Day 63. For the primary analysis at Day 63 and the sec-
ndary analyses at Day 28 and Day 42, it was hypothesized that
he proportion of subjects with TNA NF50 above 0.56 in each group
as at least 40%. This hypothesis was tested with an exact Binomial
wo-sided conﬁdence interval approach. Subjects who had missing
mmunogenicity values were not counted in the denominator.
Safety analyses were conducted on the safety population,
eﬁned as all subjects who  had received at least one vaccination.
dverse events were coded using the Medical Dictionary for Regu-
atory Activities®, version 15.1. Missing data were included in the
enominator for subjects who missed e-diary or laboratory assess-
ents.
Assuming the true proportion of subjects that reach a TNA NF50
alue of at least 0.56 is 80% on Day 63 (supported by unpublished
ata from Study EBS.AVA.201 [4]) and assuming a 10% dropout rate,
 sample size of 44 subjects (Group 1), 34 subjects (Group 2), and
3 subjects (Group 3) provided >99.0% power (Group 1) and at least
6% power (Groups 2 and 3) to obtain a two-sided 95% CI with lower
imit ≥40%.
. Results.1. Subject disposition and demographics
Trial recruitment initiated in January 2013 and completed as per
he protocol in November 2013. The last subject completed the ﬁnal4 (2016) 2096–2105
visit in February 2014 and the 12-month safety follow-up phone
contact after the last vaccination in December 2014.
Of 419 screened subjects, 168 met  eligibility requirements and
were randomized to one of the 5 groups. All 168 subjects received
at least one vaccination, hence were included in the safety pop-
ulation. A total 158 (94.0%) subjects completed through Day  84
(Fig. 1). Because subjects could be followed for safety after discon-
tinuing vaccinations for any reason, not all the completer subjects
received all vaccinations: 147 (87.5%) subjects completed Day 84
having received all vaccinations, whereas 11 (6.5%) subjects dis-
continued vaccinations while still remaining in the study through
Day 84.
Ten (6.0%) subjects discontinued prior to Day 84 (Fig. 1). Five
subjects withdrew having received all 3 vaccinations (3 were lost
to follow up; 1 was withdrawn by the sponsor; and 1 moved out
of state) and 5 withdrew without receiving all 3 vaccinations (3
withdrew consent, 1 experienced an SAE [cellulitis secondary to
animal bite], and 1 was withdrawn by the sponsor).
Subjects were equally distributed by age and gender and other
baseline characteristics across the treatment groups (Table 1). The
population was predominantly white (91.7%) followed by Black
or African American (7.1%) and of non-Hispanic/Latino descent
(82.7%).
3.2. Safety
3.2.1. Adverse events
During the in-clinic portion of the study, two subjects reported
SAEs requiring hospitalization. Following vaccination 2, a subject
in Group 1 was  withdrawn after developing cellulitis secondary to
an animal bite. After receiving all vaccinations, a subject in Group
5 experienced pyelonephritis. Both events were assessed by the
investigator as being unrelated to the vaccine.
After Day 84, an additional 2 SAEs were reported. One  SAE was
reported for the infant of a subject (Group 1) who became pregnant
after birth control restrictions were lifted. The subject delivered at
36 weeks via precautionary cesarean section because of a bicor-
nuate uterus and previous cesarean section history. The infant’s
complication of neonatal atelectasis requiring continuous positive
airway pressure was  considered unrelated to the vaccine since
this condition is not uncommon in premature births. A separate
SAE of rectal neoplasm was  reported at the ﬁnal safety follow-
up phone contact for the subject who also reported cellulitis. The
event was assessed by the investigator as being unrelated to the
vaccine.
No AESIs of potential autoimmune etiology were reported up
through the last safety follow-up phone contact.
The incidences of AEs and, as assessed by the investigator, poten-
tially treatment-related AEs were lower in the BioThrax group in
comparison with the AV7909 treatment groups. The highest inci-
dence of AEs was in Group 1 (36/44; 81.8%), followed by Group 4
(35/44; 79.5%), Group 2 (26/34; 76.5%), Group 3 (17/23; 73.9%), and
Group 5 (15/23; 65.2%). The common AEs occurring in 5% or more
of subjects in any group are provided in Table 2.
Vaccinations in all groups were well-tolerated; 92.1% (105/114)
of AV7909 subjects and 86.7% of BioThrax subjects (13/15) having
AEs reported Grade 1 or 2 AEs. Nine AEs led to vaccine discon-
tinuation in seven (7/168; 4.2%) subjects across Groups 1–3, a
proportionally higher number in Group 1 (5/44; 11.4%) compared
with Group 2 (1/34; 2.9%) or Group 3 (1/23; 4.3%). Six of the nine
AEs that led to discontinuation of vaccination were assessed as
related to the vaccine, involving 4 subjects with Grade 1 generalized
pruritus and rash (Group 2), Grade 2 rash (Group 1), Grade 2 ele-
vated transaminases (Group 1), and Grade 3 injection site erythema
(Group 3).
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o  1 of 5 study groups at a 4:3:2:4:2 ratio. One-hundred sixty-eight subjects were 
isits  through Day 84; and 147 subjects completed the in-clinic visits through Day 
No clinically relevant differences among groups in the type
r incidence of vital signs or clinical laboratory or physical exam
bnormalities were observed.
.2.2. Injection site and systemic reactogenicity (e-diary data)
Reactogenicity data represent both the common and expected
eactions with vaccination. Self-reported e-diary data were con-
idered more relevant than the in-clinic reactogenicity physician
ssessments because self-reports occurred soon after each injection
nd were more frequent. Eighteen e-diary temperature measure-
ents out of over 3500 planned assessments were taken or
ecorded improperly by subjects and excluded from analysis as they
ell outside the range of clinically plausible values.
One subject (Group 3) discontinued treatment as a result of reac-
ogenicity: Grade 3 injection site erythema of diameter >13 cm.
he systemic reactions and injection site reactions are summarized
y vaccination and severity in Fig. 2. Over half of subjects overall
eported tenderness, injection site pain, arm motion limitation, and
uscle ache after the ﬁrst vaccination. After the third vaccination,
nly tenderness was reported in more than half of subjects overall.indow; Plc = placebo; TNA = toxin neutralizing antibody. Subjects were randomized
mized and received at least one vaccination; 158 subjects completed the in-clinic
 received all 3 vaccinations.
The vast majority of subjects reported reactogenicity events that
were mild or moderate in severity (157/168 [93.5%] for injection
site reactions and 140/168 [83.3%] for systemic reactions). One sub-
ject (Group 3) reported a Grade 3 injection site reaction of warmth
after the third vaccination. Five subjects reported Grade 3 sys-
temic reactions: 4 subjects in Group 1 (fever after vaccination 1;
fatigue/tiredness, muscle ache, and headache after vaccination 1;
headache after vaccination 1; and fever after vaccination 3) and
1 subject in Group 3 (fatigue/tiredness after vaccination 2). Three
subjects downgraded their event reports from Grade 3 to Grade 2
after discussing their symptoms with investigators. There was no
discernible pattern regarding incidence or severity of reactogeni-
city events that indicated a safety concern for any of the groups.
3.3. ImmunogenicityAcross all groups, reasons for exclusion from analysis in the
PP population (N = 144 out of 168 randomized subjects) pre-
dominantly involved missing vaccination visits and missing TNA
assessments (refer to Fig. 1 for exclusion reasons).
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Fig. 2. (a) Reactogenicity after each vaccination (e-diary data)—solicited systemic reactions. Grp = group. “Plc” appearing over the treatment group denotes a placebo dose
(saline for injection) was administered to mask the vaccine schedule. Group 1 = full dose AV7909 0/14 days; Group 2 = full dose AV7909 0/28 days; Group 3 = full dose AV7909
0/14/28 days; Group 4 = half dose AV7909 0/14/28 days; Group 5 = full dose BioThrax 0/14/28 days. All doses were administered intramuscularly. Three subjects reported
severe events later downgraded to moderate after discussion with the investigator: fatigue/tiredness and headache after vaccination 2 in Group 1; headache after vaccination
2  in Group 1; fatigue/tiredness and muscle ache after vaccination 2 in Group 1 (corrected data shown in the ﬁgure). Eighteen temperature values were excluded from analysis
because  of clinical infeasibility (2 improbably high, 16 improbably low). * P < 0.05 for comparison with Group 5 (Fisher’s Exact test; analysis performed post hoc). Inferential
statistics were not performed in comparison to placebo.
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Fig. 2. (b) Reactogenicity after each vaccination (e-diary data)—solicited injection site reactions. Grp = group. “Plc” appearing over the treatment group denotes a placebo
dose  (saline for injection) was administered to mask the vaccine schedule. Group 1 = full dose AV7909 0/14 days; Group 2 = full dose AV7909 0/28 days; Group 3 = full dose
AV7909 0/14/28 days; Group 4 = half dose AV7909 0/14/28 days; Group 5 = full dose BioThrax 0/14/28 days. All doses were administered intramuscularly. One subject in
Group  1 reported events after vaccination 2 of severe pain and severe arm motion limitation later downgraded to moderate after discussion with the investigator (corrected
data  shown in the ﬁgure). * P < 0.05 for comparison with Group 5 (Fisher’s Exact test; analysis performed post hoc). Inferential statistics were not performed in comparison
to  placebo.
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Table 1
Subject demographics and baseline characteristics—ITT population.
Characteristic AV7909; AV7909;
Plc (N = 44)
AV7909; Plc;
AV7909 (N = 34)
AV7909 × 3
(N = 23)
1/2 dose
AV7909 × 3 (N = 44)
BioThrax × 3
(N = 23)
Gender, n (%)
Male 22 (50.0) 17 (50.0) 12 (52.2) 22 (50.0) 12 (52.2)
Female  22 (50.0) 17 (50.0) 11 (47.8) 22 (50.0) 11 (47.8)
Age  (years)
Mean/median 33.4/30.5 32.7/30.0 29.7/29.0 32.8/30.5 32.5/30.0
SD  9.02 9.66 10.22 9.21 10.37
Min–max 20–50 18–48 18–50 19–50 18–48
Age  group, n (%)
≤30 years 22 (50.0) 18 (52.9) 12 (52.2) 22 (50.0) 12 (52.2)
>30  years 22 (50.0) 16 (47.1) 11 (47.8) 22 (50.0) 11 (47.8)
Weight  (kg)
Mean/median 85.4/82.5 79.8/75.2 86.7/80.0 82.9/78.0 87.1/81.0
SD  22.8 20.2 26.3 19.6 18.3
Min–max 56.0–145.0 43.6–125.0 52.8–173.0 51.0–129.0 60.0–133.0
Race,  n (%)
White 40 (90.9) 33 (97.1) 20 (87.0) 40 (90.9) 21 (91.3)
Black  or African American 3 (6.8) 1 (2.9) 3 (13.0) 3 (6.8) 2 (8.7)
Othera 1 (2.3) 0 0 1 (2.3) 0
Ethnicity, n (%)
Not Hispanic or Latino 35 (79.5) 27 (79.4) 19 (82.6) 39 (88.6) 19 (82.6)
Hispanic or Latino 9 (20.5) 7 (20.6) 4 (17.4) 5 (11.4) 4 (17.4)
P l dose
A cularl
).
(
a
9
a
O
1
T
C
M
Dlc = placebo; ITT = intent-to-treat; max  = maximum; min  = minimum. AV7909 ful
VA  + 0.125 mg  CPG 7909). BioThrax dose: 0.5 mL.  All doses were injected intramus
a Other includes Asian (n = 1) and Native Hawaiian or Other Paciﬁc Islander (n = 1
Peak immune responses reﬂected immunization schedules
refer to Fig. 3). Highest GMT  peak based upon TNA NF50 occurred
fter two administrations of AV7909 on Days 0/28 (Group 2; 5.30;
5% CI: 4.09, 6.86), which was slightly greater than after three
dministrations on Days 0/14/28 (Group 3; 4.06; 95% CI: 2.52, 6.53).
ther schedules had lower peak responses: Group 4 (2.40; 95% CI:
.91, 3.02), Group 1 (1.83; 95% CI: 1.32, 2.53), and Group 5 (1.17; 95%
able 2
ommon adverse events occurring in ≥5% of subjects in any study group—safety populat
MedDRA system organ class and preferred term AV7909; AV7909;
Plc (N = 44) n (%)
AV790
AV790
(%)
Subjects with any adverse event 36 (81.8) 26 (76
Cardiac disorders 3 (6.8) 1 (2.9
Bradycardia 2 (4.5) 0 
Infections and infestations 19 (43.2) 13 (38
Nasopharyngitis 7 (15.9) 3 (8.8
Upper  respiratory tract infection 10 (22.7) 5 (14
Urinary tract infection 0 1 (2.9
Viral  infection 1 (2.3) 2 (5.9
Vulvovaginal mycotic infection 0 0 
Investigations 19 (43.2) 13 (38
Aspartate aminotransferase increased 2 (4.5) 2 (5.9
Blood  pressure diastolic decreased 5 (11.4) 3 (8.8
Blood  pressure increased 3 (6.8) 0 
Heart  rate decreased 1 (2.3) 4 (11
Protein urine present 0 0 
Red  blood cells urine positive 2 (4.5) 0*
Respiratory rate increased 6 (13.6) 2 (5.9
Musculoskeletal and connective tissue disorders 3 (6.8) 5 (14
Back  pain 2 (4.5) 2 (5.9
Respiratory, thoracic and mediastinal disorders 3 (6.8) 5 (14
Oropharyngeal pain 1 (2.3) 2 (5.9
Pharyngeal erythema 0 0 
edDRA = Medical dictionary for regulatory activities; Plc = placebo. Adverse events were 
ay  84. All adverse events occurring prior to receipt of investigational product are exclud
* P < 0.05 for comparison with the BioThrax group (Fisher’s Exact test; analysis perform
a The denominator for this gender-speciﬁc AE term is the number of women.: 0.5 mL (0.5 mL  AVA + 0.25 mg CPG 7909); AV7909 half dose: 0.25 mL  (0.25 mL
y in the deltoid on Days 0, 14, 28.
CI: 0.74, 1.84). Notably, AV7909 administered on Days 0/14 (Group
1) resulted in a higher immune response on Day 28 compared with
BioThrax IM vaccine administered on the same schedule (Group 5).
In addition, the time point at which peak immunity was  reached
reﬂected immunization schedules. Group 2 (vaccinated Days 0/28)
reached peak NF50 values on Day 42 compared with Day 35 for
Group 3 (vaccinated Days 0/14/28). Although the peak was  lower,
ion.
9; Plc;
9 (N = 34) n
AV7909 × 3
(N = 23) n (%)
1/2 dose
AV7909 × 3 (N = 44)
n (%)
BioThrax × 3
(N = 23) n (%)
.5) 17 (73.9) 35 (79.5) 15 (65.2)
) 2 (8.7) 5 (11.4) 0
1 (4.3) 5 (11.4) 0
.2) 5 (21.7) 15 (34.1) 4 (17.4)
) 0 2 (4.5) 1 (4.3)
.7) 2 (8.7) 7 (15.9) 2 (8.7)
) 2 (8.7) 1 (2.3) 0
) 0 2 (4.5) 0
0 0 2 (18.2)a
.2) 9 (39.1) 19 (43.2) 7 (30.4)
) 1 (4.3) 1 (2.3) 0
) 2 (8.7) 6 (13.6) 0
0 0 0
.8) 0 1 (2.3) 2 (8.7)
0 0 2 (8.7)
0 0* 4 (17.4)
) 4 (17.4) 10 (22.7) 2 (8.7)
.7) 2 (8.7) 5 (11.4) 0
) 0 2 (4.5) 0
.7) 3 (13.0) 2 (4.5) 3 (13.0)
) 1 (4.3) 2 (4.5) 0
2 (8.7) 0 0
assessed at every study visit after signing informed consent from Screening through
ed from this table. Adverse events were coded using MedDRA version 15.1.
ed post hoc).
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Fig. 3. (a) TNA ED50 geometric mean titers and 95% conﬁdence intervals and (b) TNA NF50 geometric mean titers and 95% conﬁdence intervals – per protocol Day 63 population.
CI  = conﬁdence interval; ED50 = 50% effective dose; GMT  = geometric mean titer; IM = intramuscular; NF50 = 50% neutralization factor; TNA = toxin neutralizing antibody. The
Per  Protocol Population at Day 63 is all randomized subjects who did not have any deviation of (1) history of anthrax vaccination; (2) missing or out of window vaccination
at  Day 14 or 28; (3) incorrect vaccine dose at one or more visits; (4) vaccine dose associated with a temperature excursion; (5) prohibited medications; or (6) missing Day
63  immunogenicity data. The horizontal line represents a TNA NF50 threshold of 0.56, established for BioThrax at Day 63. The numbers of subjects analyzed are as follows:
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roup  3, 18 subjects; Group 4, 41 subjects; and Group 5, 21 subjects. Day 42: Grou
roup  5, 20 subjects.
roup 1 reached peak NF50 values on Day 28, which were equiva-
ent to non-peak NF50 values of Group 3 at the same time point.
For the primary immunogenicity analysis, success was deﬁned
s the demonstration of the lower 95% conﬁdence limit of the per-
entage of subjects with TNA NF50 values ≥0.56 to be ≥40% at Day
3. Accordingly, the study-deﬁned success criterion was met  at Day
3 in Groups 2 (point estimate 100%; lower limit 87.2%), 3 (point
stimate 100%; lower limit 81.5%), and 4 (point estimate 90.2%;
ower limit 76.9%). Group 1 marginally missed the criterion, with a
oint estimate of 56.8% and lower 95% conﬁdence limit 39.5%. The
ame success criterion was achieved for Groups 1, 3 and 4 at Day
8 and all groups at Day 42 (see Fig. 4).jects; and Group 5, 21 subjects. Day 28: Group 1, 37 subjects; Group 2, 27 subjects;
7 subjects; Group 2, 26 subjects; Group 3, 18 subjects; Group 4, 41 subjects; and
4. Discussion
AV7909 vaccine is expected to achieve, compared with BioThrax
vaccine, higher serum TNA levels, an accelerated immune response,
and fewer injections to confer protection. This would potentially
result in shorter courses of antimicrobials, hence reduced side
effects and non-compliance. An additional goal is to reduce the
amount of each vaccine component needed to establish protective
immunity in a post-exposure setting. The results of this study are
broadly applicable to a relatively young (≤50 years), mostly white,
healthy adult population. The primary outcome was based upon
achieving serum immune responses at Day 63 that meet or exceed
2104 R.J. Hopkins et al. / Vaccine 34 (2016) 2096–2105
Fig. 4. Proportion of subjects with TNA NF50 ≥ 0.56, per protocol Day 63 population. The per protocol population at Day 63 is all randomized subjects who did not have any
deviation of (1) history of anthrax vaccination; (2) missing or out of window vaccination at Day 14 or 28; (3) incorrect vaccine dose at one or more visits; (4) vaccine dose
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issociated with a temperature excursion; (5) prohibited medications; or (6) missing
roup  2, 27 subjects; Group 3, 18 subjects; Group 4, 41 subjects; and Group 5, 21 
40%  at Day 63.
he threshold of protection derived from previously conducted ani-
al  studies for BioThrax vaccine [6].
No autoimmune-related AEs were reported and otherwise no
ew safety signals were identiﬁed with use of the CpG-adjuvanted
accine. Subjects reported more AEs in the AV7909 groups vs. the
ioThrax group. However, no pattern by type or severity of AE
merged across groups. While a previous study [8,10] has shown
igniﬁcantly enhanced injection site reactogenicity for BioThrax
accine when administered using the SC vs. IM route, phase 3 test-
ng will evaluate AV7909 IM vs. the recently licensed BioThrax
accine schedule for PEP administered SC. Overall, all AV7909 doses
nd schedules in the current study were well tolerated.
All AV7909 doses and schedules evaluated met  the success cri-
erion at Day 63 by a large margin (Groups 2–4) or narrowly missed
he criterion (Group 1). The BioThrax group (Group 5) failed to meet
his success criterion on Day 63, which differs from previous Bio-
hrax vaccine studies [5,6] and is likely explained by low sample
ize and/or difference in route of administration (IM vs. SC) [8].
To achieve the goal of PEP, immune responses must be rapid and
urable. Protection at early time points is important for individuals
ho are not adherent with or cannot tolerate PEP antimicrobials.
t time points beyond the currently recommended 60-day antimi-
robial course, latent B. anthracis spores may  germinate [9]. The
NA NF50 GMTs for subjects receiving AV7909 administered on
ays 0/14 (Groups 1 and 3) and administered only on Day 0
Group 2) showed greater immune responses at the early Day 21
ssessment time point compared to subjects administered Bio-
hrax vaccine. Starting on Day 42, the TNA NF50 GMT  curves for
roups 1 and 5 essentially overlapped (Fig. 3), illustrating identical
ates of immune decay.
Highest serum peak TNA NF50 titers were achieved similarly
ith two vaccinations (Days 0/28) or three vaccinations (Days
/14/28) but were achieved 7 days earlier (Day 35) with 3 vacci-
ations. TNA NF50 responses for these two groups were equivalent
y Day 42 and were equivalently durable. The Day 0/14 regimen
as associated with higher circulating antibody levels between
ays 21 and 35 than the Day 0/28 regimen. This early protection
s critical in individuals who are not able to take the full course of3 immunogenicity data. The numbers of subjects analyzed are Group 1, 37 subjects;
ts. Success was pre-deﬁned as the lower bound of the 95% conﬁdence limit being
the currently-recommended 60-day antimicrobial regimen for PEP.
Since non-compliance is common and cannot be predicted a priori,
the Day 0/14 regimen provides reassurance that early protection
will be present even in poorly compliant patients.
Serum antibody decay rates for the AV7909 groups and Bio-
Thrax group were similar suggesting that the addition of the CPG
7909 adjuvant does not have a negative effect on the rate of anti-
body clearance within humans after the acquisition of a peak serum
concentration. Of note, BioThrax vaccine in this study was  admin-
istered IM,  which is not the licensed route of administration for
PEP. Comparison to the IM route of BioThrax vaccine allowed for a
direct assessment of the relative contribution of CPG7909 to Bio-
Thrax vaccine after 2 doses (Days 21 and 28). A previous study
[8,10] demonstrated that the immune response to BioThrax vac-
cine administered SC trended higher than when administered IM.
The anti-PA enzyme-linked immunosorbent assay geometric mean
concentrations were 49.7 vs. 30.8 g/mL for BioThrax SC vaccine
vs. BioThrax IM vaccine at Week 4 (after 2 doses on Weeks 0/2)
and 94.3 vs. 84.5 g/mL, respectively, at Week 8 (after 3 doses on
Weeks 0/2/4). Phase 3 testing will compare AV7909 IM to BioThrax
SC vaccine using the licensed schedule for PEP.
The threshold of protection used in this study (NF50 0.56) was
derived from previous BioThrax studies that utilized a pre-exposure
prophylaxis model in which BioThrax vaccine was administered
to rabbits on Day 0 and Day 28 and challenged with B. anthracis
spores on Day 70 [6]. At the time of planning for the current study,
a threshold of protection had not been derived for AV7909 and
the applicability of the BioThrax vaccine threshold for AV7909 was
uncertain.
Nonclinical studies to determine a TNA NF50 threshold speciﬁc
for AV7909 using appropriate animal models are ongoing. Current
(unpublished) data suggest that a TNA NF50 value that correlates
to an equivalent probability of survival (70%) is lower for AV7909
compared with BioThrax vaccine. This is not unexpected based
upon CPG 7909 effects which expanded the high afﬁnity B cell
memory population in mice [11] and enhanced antibody afﬁnity
maturation in humans [12]. Although these effects have not been
established for AV7909, they may  partly explain why  survival is
ccine 3
h
A
1
v
b
T
A
t
m
a
t
t
d
p
t
h
o
s
a
5
s
e
r
d
r
h
C
s
W
p
(
c
A
m
m
a
[
[R.J. Hopkins et al. / Va
igher at similar TNA NF50 values for AV7909 vs. BioThrax vaccine.
V7909 delivered IM in humans [4] on Days 0 and 14 resulted in a
.77-fold and 2.22-fold higher average avidity for PA than BioThrax
accine on Day 28 (P = 0.068) and Day 56 (P = 0.13), respectively,
ased upon a small population of 7–16 subjects (unpublished data).
his preliminary observation is consistent with the possibility that
V7909 is equally protective at lower TNA values. Regardless of
he mechanism responsible for a lower threshold of protection as
easured by the TNA NF50 value for AV7909 vs. BioThrax vaccine,
 lower threshold will likely provide both rapid and prolonged pro-
ective immunity for AV7909 using the Day 0/14 schedule. While
he Day 0/28 AV7909 schedule is associated with an even more
urable immune response, it likely does not afford the level of early
rotection seen with the Day 0/14 schedule of AV7909.
Of interest, the TNA NF50 GMT  curve for Group 4 was  essen-
ially identical to that for the BioThrax group except was  offset with
igher titers at each time point. This schedule of three half doses
f AV7909 administered 2 weeks apart may  be a viable vaccine-
paring strategy in the event of limited supply during a large-scale
nthrax attack.
. Conclusions
AV7909 vaccine was safe and well tolerated. The primary and
econdary immunogenicity outcomes of this study provide the nec-
ssary rationale for further clinical studies of an AV7909 2-dose
egimen given 2 weeks apart using larger sample sizes. The 0/14
ay schedule for full dose AV7909 showed a comparable immune
esponse to a 0/14/28 day BioThrax vaccine schedule but had a
igher and earlier peak.
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